ArticleScientific reports2026
Pertussis resurgence after the COVID-19 pandemic in four Western Pacific Countries and the USA, highlighting the 2025 outbreak in Japan.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis is a re-emerging, highly contagious respiratory disease posing a significant public health challenge globally. This retrospective study characterized the divergent pertussis resurgence after the coronavirus-disease-2019 (COVID-19) pandemic by analyzing national surveillance data from four countries of the Western Pacific region (Japan, Australia, New Zealand, China) and the United States of America, with a focus on characterizing the unique outbreak in Japan. A significant outbreak began relatively late in Japan in 2025; as of July 31, 2025 (a 7 month partial count, potentially underestimated), the country had recorded 60,826 cases (incidence rate 49.13/100,000 population), substantially exceeding the 4054 cases of the previous year. This surge stands in contrast to the earlier 2024 peaks and subsequent decreases in the other four study countries. All five countries experienced a significant increase in cases between the preventive measures phases of the COVID-19 (2020-2022) and the loosening of these measures (2023-2025) (p < 0.001). Japan's 2025 resurgence was characterized by high incidence among individuals aged 5-19 years, particularly adolescents (56.6% of cases), and concentrated in non-metropolitan prefectures. This resurgence, which may be linked to the lack of routine booster vaccinations, highlights the need to re-evaluate national immunization strategies to control the evolving threat of pertussis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.